Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00566722
First received: December 1, 2007
Last updated: April 8, 2011
Last verified: April 2011
Results First Received: April 28, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Psoriasis
Intervention: Biological: adalimumab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients who were previously treated with etanercept, methotrexate (MTX), or narrow-band ultraviolet-B (NB-UVB) and had a sub-optimal response were recruited for participation in the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants who were receiving more than 1 of the treatments (etanercept, MTX, NB-UVB) at the time of screening must have discontinued 1 therapy (e.g., MTX) at least 30 days before first dose of adalimumab and must have discontinued the other therapy (e.g., NB-UVB) during a specified time before first dose of adalimumab. See Detailed Description.

Reporting Groups
  Description
Sub-optimal Response to MTX MTX treatment must have been administered for at least 4 consecutive months prior to Screening, with no treatment interruptions except for toxicity or intolerability. If there had been a treatment interruption due to toxicity or intolerability, the length of treatment interruption could not have exceeded 14 days. If there was more than one treatment interruption due to toxicity or intolerability (regardless of the length of the treatment interruptions), the participant was not eligible. The last dose of methotrexate must have been at least 4 days but not more than 10 days before the first dose of adalimumab. Suboptimal response was defined as a Physician's Global Assessment of mild (2) or worse.
Sub-optimal Response to Narrow-band Ultraviolet-B NB-UVB must have been administered for at least 2 consecutive months prior to Screening, with no treatment interruptions except for toxicity or intolerability. If there had been a treatment interruption due to toxicity or intolerability, the length of treatment interruption could not have exceeded 14 days. If there was more than one treatment interruption due to toxicity or intolerability (regardless of the length of the treatment interruptions), the participant was not eligible. The last treatment with NB UV-B must have been at least 4 days but not more than 10 days before the first dose of adalimumab. Suboptimal response was defined as Physician's Global Assessment of moderate (3) or worse.
Sub-optimal Response to Etanercept Etanercept treatment must have been administered for at least 6 consecutive months (or at least 3 consecutive months with deterioration of efficacy observed during the 3 months) prior to Screening, with no treatment interruptions except for toxicity or intolerability, at doses of 50 mg every other week, 50 mg every week, or 25 mg every other week. A treatment interruption due to toxicity or intolerability could not have exceeded 14 days. If there was more than one treatment interruption due to toxicity or intolerability, the participant was not eligible. The last dose of etanercept must have been at least 11 days but not more than 17 days before the first dose of adalimumab. Suboptimal response was defined as a Physician's Global Assessment of mild (2) or worse.

Participant Flow:   Overall Study
    Sub-optimal Response to MTX     Sub-optimal Response to Narrow-band Ultraviolet-B     Sub-optimal Response to Etanercept  
STARTED     41     29     82  
COMPLETED     39     24     73  
NOT COMPLETED     2     5     9  
Adverse Event                 0                 1                 0  
Withdrawal by Subject                 0                 0                 1  
Lost to Follow-up                 1                 1                 1  
Lack of Efficacy                 1                 2                 4  
Did not meet exclusion criteria                 0                 0                 2  
Serious adverse event                 0                 1                 0  
Noncompliant with drug administration                 0                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sub-optimal Response to MTX MTX treatment must have been administered for at least 4 consecutive months prior to Screening, with no treatment interruptions except for toxicity or intolerability. If there had been a treatment interruption due to toxicity or intolerability, the length of treatment interruption could not have exceeded 14 days. If there was more than one treatment interruption due to toxicity or intolerability (regardless of the length of the treatment interruptions), the participant was not eligible. The last dose of methotrexate must have been at least 4 days but not more than 10 days before the first dose of adalimumab. Suboptimal response was defined as a Physician's Global Assessment of mild (2) or worse.
Sub-optimal Response to Narrow-band Ultraviolet-B NB-UVB must have been administered for at least 2 consecutive months prior to Screening, with no treatment interruptions except for toxicity or intolerability. If there had been a treatment interruption due to toxicity or intolerability, the length of treatment interruption could not have exceeded 14 days. If there was more than one treatment interruption due to toxicity or intolerability (regardless of the length of the treatment interruptions), the participant was not eligible. The last treatment with NB UV-B must have been at least 4 days but not more than 10 days before the first dose of adalimumab. Suboptimal response was defined as Physician's Global Assessment of moderate (3) or worse.
Sub-optimal Response to Etanercept Etanercept treatment must have been administered for at least 6 consecutive months (or at least 3 consecutive months with deterioration of efficacy observed during the 3 months) prior to Screening, with no treatment interruptions except for toxicity or intolerability, at doses of 50 mg every other week, 50 mg every week, or 25 mg every other week. A treatment interruption due to toxicity or intolerability could not have exceeded 14 days. If there was more than one treatment interruption due to toxicity or intolerability, the participant was not eligible. The last dose of etanercept must have been at least 11 days but not more than 17 days before the first dose of adalimumab. Suboptimal response was defined as a Physician's Global Assessment of mild (2) or worse.
Total Total of all reporting groups

Baseline Measures
    Sub-optimal Response to MTX     Sub-optimal Response to Narrow-band Ultraviolet-B     Sub-optimal Response to Etanercept     Total  
Number of Participants  
[units: participants]
  41     29     82     152  
Age  
[units: years]
Mean ± Standard Deviation
  47.4  ± 13.11     45.7  ± 14.60     48.3  ± 13.70     47.6  ± 13.67  
Gender  
[units: participants]
       
Female     13     13     35     61  
Male     28     16     47     91  
Region of Enrollment  
[units: participants]
       
United States     26     10     70     106  
Canada     15     19     12     46  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16   [ Time Frame: Week 16 ]

2.  Secondary:   Number of Participants Achieving a PGA of Clear (0) at Week 16   [ Time Frame: Week 16 ]

3.  Secondary:   Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening   [ Time Frame: From Screening to Week 16 ]

4.  Secondary:   Number of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8   [ Time Frame: Weeks 2, 4, and 8 ]

5.  Secondary:   Dermatology Life Quality Index (DLQI) Total Score   [ Time Frame: From Screening to Week 4 and Week 16 ]

6.  Secondary:   Number of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16   [ Time Frame: Week 4 and Week 16 ]

7.  Secondary:   Psoriasis-related Pruritus Assessment   [ Time Frame: From Screening to Week 16 ]

8.  Secondary:   Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis   [ Time Frame: From Screening to Week 16 ]

9.  Secondary:   Percent Work Time Missed Due to Psoriasis   [ Time Frame: From Screening to Week 16 ]

10.  Secondary:   Percent Overall Work Impairment Due to Psoriasis   [ Time Frame: From Screening to Week 16 ]

11.  Secondary:   Percent Impairment While Working Due to Psoriasis   [ Time Frame: From Screening to Week 16 ]

12.  Secondary:   Percent Activity Impairment Due to Psoriasis   [ Time Frame: From Screening to Week 16 ]

13.  Secondary:   Sleep Problems Index II   [ Time Frame: From Screening to Week 16 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Global Medical Services
Organization: Abbott
phone: 800-633-9110


No publications provided by Abbott

Publications automatically indexed to this study:

Responsible Party: Marie Rosenfeld, CRM, Abbott
ClinicalTrials.gov Identifier: NCT00566722     History of Changes
Other Study ID Numbers: M10-238
Study First Received: December 1, 2007
Results First Received: April 28, 2010
Last Updated: April 8, 2011
Health Authority: United States: Food and Drug Administration